$TEM

Rogers James William sold $634K of TEM

Rogers James William (Chief Financial Officer) sold 11,529 shares of Tempus AI, Inc. (TEM) at $55.00 ($0.63M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rogers James William
Published Jun 30, 2026, 12:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The disclosed event is an open-market sale by the CFO for ~$634k, executed under a pre-arranged 10b5-1 plan; this is generally treated as routine unless paired with other negative fundamentals.

02

Market read

Traders may monitor for insider selling trends, but this specific disclosure is unlikely to drive a major repricing on its own.

03

What to watch

The filing does not disclose reasons for the sale beyond the existence of a 10b5-1 plan; without additional context (e.g., other insiders buying, earnings timing), the signal is weak.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed late June 29; sale dated June 25.

Background

The article summarizes an SEC Form 4 insider transaction for Tempus AI, Inc. (TEM) involving the CFO.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI CFO Rogers James William sold 11,529 shares in an open-market transaction for about $634,095 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale (not a buy), but it is explicitly tied to a pre-arranged 10b5-1 plan, reducing the likelihood of new, time-sensitive negative information.

Market effects

Minimal—this is company-specific insider transaction data with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still reflect management’s view of valuation or liquidity needs; traders may still fade rallies if selling cadence continues.

Key entities

  • Tempus AI, Inc.

    Issuer of the Form 4 insider transaction; ticker TEM.

  • Rogers James William

    Chief Financial Officer who sold 11,529 shares.

  • 10b5-1 plan

    Pre-arranged trading plan that reduces the informational content of the sale timing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEMMedAI 8/10

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

$TEMMed

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

$TEMHighAI 9/10

Tempus AI gets FDA clearance for pulmonary hypertension AI tool

Tempus AI (NASDAQ: TEM) received FDA clearance for its AI tool, Tempus ECG-PH, which analyzes ECGs for pulmonary hypertension. This is the third FDA-cleared device in its cardiovascular portfolio. Tempus shares rose 5.09% to $70.04, driven by positive Phase 3 trial results from Moderna and Merck, which validate the $1.5 billion acquisition of Personalis.